Active	Status	Sponsor type	Region	Phase	Filter
8 Active 5 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Merli, Francesco
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma	Recruiting	3	870	Europe	R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)	Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum	Mantle Cell Lymphoma	05/21	05/26
RENOIR, NCT02390869 / 2012-003392-18: Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients	Active, not recruiting	3	128	Europe	R2-MANT, Rituximab and Lenalidomide (R2), R-MANT, Rituximab (R)	Fondazione Italiana Linfomi - ETS	Lymphoma, Follicular	01/23	12/27
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy	Recruiting	3	430	Europe	Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses	Fondazione Italiana Linfomi ONLUS, GRADE Onlus	Diffuse Large B-Cell Lymphoma, Elderly Patients	09/25	09/30
NCT02371161 / 2013-003256-20: Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy	Recruiting	2	135	Europe	R-DHAP/R-ICE, R-DHAP or R-ICE and BEAM or FEAM	Fondazione Italiana Linfomi ONLUS	Non Hodgkin Lymphoma	12/18	02/23
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance	Recruiting	2	90	Europe	Ibrutinib, IMBRUVICA (commercial name)	Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.	DLBCL	06/24	07/27
FIL_DALYA, NCT04915248 / 2020-000409-94: Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.	Recruiting	2	28	Europe	Daratumumab, Daratumumab sc, Bortezomib, Bortezomib sc, Dexamethasone, Dexamethasone os	Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.	Plasmablastic Lymphoma	06/24	06/24
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance	Recruiting	N/A	250	Europe		Ospedale di Circolo - Fondazione Macchi	SARS-CoV-2 Infection, Hematological Malignancies	10/22	10/22
NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis	Recruiting	N/A	400	Europe	Treatment for clinical practise	Fondazione Italiana Linfomi ONLUS	Classical Hodgkin Lymphoma	01/26	01/26